MYPN Antibody

What is MYPN and why is it significant in muscle research?

Myopalladin (MYPN) is a striated muscle-specific immunoglobulin domain-containing protein primarily localized in the sarcomeric Z-line and I-band of muscle cells . It functions as a critical sarcomeric component that tethers nebulin (in skeletal muscle) and nebulette (in cardiac muscle) to alpha-actinin at the Z-lines . This tethering is essential for maintaining sarcomeric structure and function. MYPN research is particularly significant because mutations in the MYPN gene have been causatively linked to several cardiomyopathies, including dilated, hypertrophic, and restrictive forms , as well as nemaline myopathy, a congenital nondystrophic skeletal muscle disease .

What are the commonly available types of MYPN antibodies for research?

Currently, the most commonly utilized MYPN antibodies in research are rabbit polyclonal antibodies. Commercial suppliers such as Abcam and Atlas Antibodies produce rabbit polyclonal anti-MYPN antibodies suitable for various experimental applications . The immunogen typically corresponds to recombinant fragment proteins within the human MYPN amino acid sequence, often targeting the region from residue 900 to the C-terminus . While monoclonal antibodies may also be available, the literature predominantly references the use of polyclonal antibodies for MYPN detection and characterization.

What are the validated applications for MYPN antibodies in muscle research?

MYPN antibodies have been validated for several experimental applications, primarily:

• Western Blotting (WB): Effective for detecting MYPN in tissue lysates, particularly from heart and skeletal muscle, typically at concentrations around 2 μg/mL .

• Immunohistochemistry on Paraffin-embedded tissues (IHC-P): Successfully used for localizing MYPN in formalin-fixed, paraffin-embedded human skeletal muscle tissues at concentrations around 20 μg/ml .

• Immunofluorescence: Some studies note challenges with immunofluorescence applications; in such cases, researchers have employed alternative approaches such as expressing fluorescently tagged MYPN (e.g., PmCherry-N1-MYPN) to study localization .

How should protein samples be prepared for optimal MYPN detection in Western blots?

For optimal MYPN detection in Western blotting:

• Tissue selection: MYPN is expressed in striated muscles, so cardiac and skeletal muscle tissues are preferred. Pig heart and skeletal muscle lysates have been successfully used for antibody validation .

• Protein extraction: Standard protein extraction protocols using RIPA buffer with protease inhibitors are generally effective. Due to the sarcomeric localization of MYPN, special care should be taken to ensure thorough homogenization of muscle tissue.

• Protein loading: Given MYPN's relatively high molecular weight (145 kDa), using lower percentage (7-8%) SDS-PAGE gels or gradient gels is recommended for better separation.

• Secondary antibody selection: HRP-Linked Guinea pig Anti-Rabbit antibody at 1/1000 dilution has been successfully used in conjunction with rabbit polyclonal MYPN antibodies .

What are the best approaches for MYPN localization studies in muscle tissues?

For MYPN localization studies in muscle tissues, researchers should consider:

• IHC-P: For formalin-fixed, paraffin-embedded tissues, anti-MYPN antibody at approximately 20 μg/ml with DAB (3,3'-diaminobenzidine) staining has proven effective .

• Immunofluorescence challenges: Some research notes that certain MYPN antibodies do not work well for immunofluorescence staining . In such cases, alternatives include:

  • Expressing fluorescently tagged MYPN by electroporation into muscle tissue (e.g., using PmCherry-N1-MYPN in tibialis anterior muscle) .

  • Using confocal microscopy with a high-quality oil immersion lens for improved resolution.

  • Co-staining with Z-line markers such as anti-α-actinin to confirm proper localization, as MYPN should colocalize with α-actinin at the Z-line in normal muscle .

What are common issues in MYPN immunostaining and how can they be addressed?

Several challenges may arise in MYPN immunostaining:

• Poor or absent staining: This could indicate antibody quality issues, improper tissue fixation, or absence of MYPN in pathological samples. Verification strategies include:

  • Using positive control tissues (normal skeletal or cardiac muscle)

  • Testing alternative antibody concentrations (ranging from 10-30 μg/ml)

  • Optimizing antigen retrieval methods for paraffin sections

  • Confirming MYPN expression using complementary methods (e.g., RT-PCR)

• Non-specific staining: May occur due to cross-reactivity. Solutions include:

  • Increasing blocking time and concentration

  • Further diluting the primary antibody

  • Using tissue from MYPN knockout models as a negative control

• Difficulty with immunofluorescence: As noted in research, some MYPN antibodies perform poorly in immunofluorescence . Alternative approaches include:

  • Using fluorescently tagged MYPN expression constructs

  • Trying different fixation methods

  • Testing multiple antibodies targeting different MYPN epitopes

How can researchers verify the specificity of MYPN antibody signals?

To ensure the specificity of MYPN antibody signals, researchers should implement several validation approaches:

• Knockout/knockdown controls: Tissues or cells lacking MYPN expression should show no signal. MYPN knockout mice are available and have been characterized .

• Peptide competition assays: Pre-incubating the antibody with immunizing peptide should abolish specific signals.

• Multiple antibody validation: Using different antibodies targeting distinct MYPN epitopes should yield consistent localization patterns.

• Western blot correlation: Verify that immunostaining results correlate with Western blot findings, including the absence of full-length MYPN in samples from individuals with truncating mutations .

• Colocalization studies: In normal muscle, MYPN should colocalize with α-actinin at the Z-line, providing a functional validation of proper staining .

How should researchers interpret altered MYPN staining patterns in disease models?

When interpreting altered MYPN staining patterns in pathological samples:

• Complete absence of staining: May indicate nonsense or frameshift mutations leading to absence of protein, as observed in samples from individuals with certain MYPN mutations . This should be verified by Western blot.

• Reduced intensity: Could suggest decreased expression or partial protein degradation, potentially correlating with milder phenotypes.

• Altered localization: May indicate structural disruption of the sarcomere. In normal muscle, MYPN colocalizes with α-actinin at the Z-line; deviation from this pattern may signify pathology .

• Correlation with ultrastructural findings: Altered MYPN staining should be correlated with electron microscopy observations, such as Z-streaming or nemaline-like bodies adjacent to disorganized Z-lines, as seen in MYPN mutant models .

How can MYPN antibodies be used to study interactions with other sarcomeric proteins?

MYPN antibodies can be valuable tools for studying protein-protein interactions in the sarcomere through several advanced approaches:

• Co-immunoprecipitation (Co-IP): Using anti-MYPN antibodies to pull down MYPN and its interacting partners, such as nebulin, nebulette, and α-actinin. This approach can identify binding partners and assess how pathogenic mutations affect these interactions.

• Proximity ligation assays (PLA): This technique can detect and quantify protein interactions in situ, allowing the assessment of MYPN's proximity to other sarcomeric proteins in normal and pathological muscle.

• FRET analysis: By combining fluorescently labeled MYPN antibodies with antibodies against potential interaction partners, researchers can assess spatial proximity in the range of 1-10 nm.

• Dual immunostaining: Comparing localization patterns of MYPN with its known binding partners (nebulin, α-actinin) in normal and disease tissue can provide insights into altered interactions . For example, research has examined whether nebulin localization is altered in tissues lacking MYPN .

What approaches can be used to study MYPN in the context of sarcomeric assembly and maintenance?

Studying MYPN's role in sarcomeric assembly and maintenance requires sophisticated experimental designs:

• Live cell imaging: Using fluorescently tagged MYPN constructs to monitor its dynamics during sarcomere assembly in primary cardiomyocytes or myocytes.

• Inducible knockout/knockdown systems: Temporal control of MYPN expression can help distinguish between its roles in sarcomere assembly versus maintenance.

• CRISPR-Cas9 gene editing: Introduction of disease-associated MYPN mutations to study their effects on sarcomere structure.

• Electron microscopy combined with immunogold labeling: This approach can precisely localize MYPN at the ultrastructural level and assess how its absence affects sarcomeric organization, such as Z-line structure and actin filament length .

• Measurement of actin filament length: Phalloidin staining and/or electron microscopy can assess whether MYPN deficiency affects the thin filament architecture of the sarcomere .

How do MYPN antibodies contribute to understanding pathophysiological mechanisms in cardiomyopathies and myopathies?

MYPN antibodies provide crucial insights into disease mechanisms through:

• Diagnostic histopathology: Identifying characteristic changes in MYPN expression or localization in muscle biopsies from patients with cardiomyopathies or nemaline myopathy.

• Genotype-phenotype correlations: Assessing how different MYPN mutations affect protein expression, localization, and interactions, helping to explain clinical variability.

• Mechanical studies: Combined with functional assays, MYPN immunostaining helps correlate structural changes with altered mechanical properties, such as decreased myofibrillar isometric tension generation and increased resting tension observed in MYPN knockout mice .

• Signaling pathway analysis: MYPN is involved in the serum response factor (SRF) signaling pathway, which promotes skeletal muscle growth . Antibodies can help track alterations in this pathway in disease states.

• Therapeutic development: Tracking MYPN expression and localization in response to experimental therapies can serve as a biomarker for treatment efficacy.

How should MYPN antibodies be applied in the study of nemaline myopathy?

For nemaline myopathy research, MYPN antibodies require specific considerations:

• Rod identification: In nemaline myopathy, characteristic rod-like structures can be present in myofibers. MYPN antibodies, combined with other sarcomeric protein markers, can help characterize the composition of these rods.

• Intranuclear rod assessment: Some forms of nemaline myopathy, including those associated with MYPN mutations, feature intranuclear rods . Special staining protocols may be needed to properly identify these structures.

• Clinical correlation: MYPN mutations are associated with relatively mild, childhood- to adult-onset nemaline myopathy with slowly progressive muscle weakness . Correlating antibody staining patterns with clinical severity can provide mechanistic insights.

• Comparative analysis: Investigating differences in MYPN expression and localization between MYPN-associated nemaline myopathy and forms caused by mutations in other genes (such as ACTA1).

• Therapeutic monitoring: Using MYPN antibodies to assess sarcomeric remodeling in response to experimental treatments.

What are the key considerations when using MYPN antibodies to study cardiomyopathies?

In cardiomyopathy research, MYPN antibody applications require attention to:

• Cardiac-specific isoforms: Ensuring that the antibody recognizes cardiac-expressed MYPN isoforms.

• Differentiation between cardiomyopathy types: MYPN mutations have been associated with dilated, hypertrophic, and restrictive cardiomyopathies . Distinctive staining patterns may correlate with these different phenotypes.

• Intercalated disc assessment: In MYPN knockout mice, increased intercalated disc fold amplitude has been observed . Special attention to these structures during immunostaining can provide insights into mechanical coupling between cardiomyocytes.

• Fibrosis correlation: Cardiomyopathies often feature fibrosis. Dual staining with MYPN antibodies and fibrosis markers can help understand the relationship between sarcomeric disorganization and fibrotic remodeling.

• Pressure overload response: MYPN knockout mice show a normal hypertrophic response to transaortic constriction initially, followed by rapid development of severe cardiac dilation and dysfunction . Temporal analysis of MYPN expression during pressure overload can illuminate adaptive versus maladaptive remodeling.

How can the absence of MYPN staining be interpreted in the context of genetic mutations?

The absence of MYPN staining in tissue samples requires careful interpretation:

• Mutation verification: Complete absence of MYPN staining suggests nonsense, frameshift, or splice-site mutations that markedly decrease MYPN levels . This should be confirmed by genetic analysis.

• Western blot correlation: Absence of staining should be verified by Western blot to confirm the complete lack of full-length MYPN protein .

• Functional consequences: The absence of MYPN likely affects the maintenance of sarcomeric structure . This can be assessed through detailed ultrastructural analysis and functional studies.

• Compensatory mechanisms: Investigation of related proteins (such as palladin or myotilin) may reveal compensatory upregulation in the absence of MYPN.

• Therapeutic implications: Complete absence versus reduced expression may indicate different approaches for potential therapies (e.g., gene replacement versus protein stabilization).